Other (Income)/Deductions—Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025		Jun. 30, 2024
Loss Contingencies [Line Items]
Net (gains) losses recognized during the period on equity securities	[1]	$ (75)	$ 342	$ 295	[2]	$ 317	[2]
Net unrealized losses	[3]	(65)	344	1,230		533
Intangible asset impairment charge				317
ViiV [Member]
Loss Contingencies [Line Items]
Dividend income						135
License [Member] | Biopharma [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge				210
IPR&D [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[4],[5]			93
IPR&D [Member] | Biopharma [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge			240			240
Haleon [Member]
Loss Contingencies [Line Items]
Net (gains) losses recognized during the period on equity securities				144
Net unrealized losses				1,000
Gain on sale of equity method investment				900		150
ViiV [Member]
Loss Contingencies [Line Items]
Dividend income			$ 74	$ 111		$ 135
ViiV [Member] | Biopharma [Member]
Loss Contingencies [Line Items]
Dividend income		$ 73

[1] Reported in Other (income)/deductions––net. See Note 4.

[2] The net losses in the first six months of 2025 include, among other things, a net loss of $144 million related to our investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment.

[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of June 29, 2025, there were cumulative impairments and downward adjustments of $435 million and upward adjustments of $239 million. Impairments, downward and upward adjustments were not material to our operations in the second quarters and first six months of 2025 and 2024.

[4] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

[5] See Note 9.